| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:SQ 29,548
CAS:98672-91-4
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Shanghai Universal Biotech Co.,Ltd
|
| Tel: |
18768175414 |
| Email: |
gaojun@univ-bio.com |
| Products Intro: |
Product Name:SQ 29,548
CAS:98672-91-4
Package:1mg Remarks: 见优宁维官网
|
| Company Name: |
ApexBio Technology
|
| Tel: |
+ 1-832-696-8203 |
| Email: |
sales@apexbt.com |
| Products Intro: |
Product Name:SQ 29,548
CAS:98672-91-4
|
|
| | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT Basic information |
| Product Name: | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT | | Synonyms: | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT;(Z)-7-[(1R,4S)-3α-[[2-[(Phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]heptan-2α-yl]-5-heptenoic acid;BMS-18290;1S-[1α,2β(5Z),3β,4α]]-7-[3-[2-(Phenylcarbamoyl)hydrazinomethyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid;RJNDVCNWVBWHLY-BHQIHCQQSA-N;5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[[2-[(phenylamino)carbonyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-, (5Z)-;1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoicacid | | CAS: | 98672-91-4 | | MF: | C21H29N3O4 | | MW: | 387.47 | | EINECS: | | | Product Categories: | | | Mol File: | 98672-91-4.mol |  |
| | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT Chemical Properties |
| Melting point | 92-95 °C | | density | 1?+-.0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≤0.9mg/ml in ethanol;5mg/ml in DMSO;0.14mg/ml in dimethyl formamide | | form | White to off-white crystalline powder. | | pka | 4.76±0.10(Predicted) |
| | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT Usage And Synthesis |
| Description | SQ 29,548 is a highly selective TP receptor antagonist which binds to the human recombinant TP receptor with a Ki of 4.1 nM. It inhibits the aggregation of washed human platelets induced by U-46619 with an IC50 of 0.06 μM. It antagonizes U-46619 induced contraction of rat and guinea pig tracheal, arterial, and venous smooth muscles with drug/receptor dissociation constants (KB) in the range of 0.5-1.7 nM. SQ 29,548 also inhibits the contraction of rat vascular smooth muscle induced by 8-iso PGF2α. | | Uses | SQ-29548 is a potent and selective thromboxane A2 receptor antagonist. | | in vitro | in guinea-pig trachea and rat aorta, sq 29,548 competitively antagonized the activity of 9,11-azo pgh2 with pa2 values of 7.8 and 8.4, respectively. sq 29,548 competitively antagonized contractions of guinea-pig tracheal spirals induced by 11,9-epoxymethano pgh2 with the pa2 value of 9.1. the sq 29,548 competitively antagonized tracheal induced by 11,9-epoxymethano pgh2 and pgd2 with the pa2 values of 8.2 and 8.3, respectively. sq 29,548 partially antagonized the contractions of guinea-pig tracheal spirals caused by pge2. sq 29,548 significantly inhibited the aorta contracting activity of 11,9-epoxymethano pgh2 (pa2 = 9.1) and thromboxane a2 released from perfused guinea-pig lungs upon arachidonic acid challenge [1]. | | in vivo | in anesthetized dogs, sq 29,548 (0.2 mg/kg/h) completely inhibited the vasoconstrictor response of the left circumflex coronary artery (lcx) caused by u-46619. sq 28,585 showed no effects on infarct size as compared with vehicle controls [3]. in sham mi rats, treatment with sq-29,548 significantly blunted this loss of ck activity and amino-nitrogen concentration from the ischemic myocardium. sq-29,548 significantly prevented the extension of ischemic damage in the myocardium and improved survival following acute coronary artery ligation [4]. | | references | [1] ogletree m l, harris d n, greenberg r, et al. pharmacological actions of sq 29,548, a novel selective thromboxane antagonist[j]. journal of pharmacology and experimental therapeutics, 1985, 234(2): 435-441.
[2] abe t, takeuchi k, takahashi n, et al. rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization[j]. journal of clinical investigation, 1995, 96(2): 657.
[3] grover g j, schumacher w a. effect of the thromboxane receptor antagonist sq 29,548 on myocardial infarct size in dogs[j]. journal of cardiovascular pharmacology, 1988, 11(1): 29-35.
[4] hock c e, brezinski m e, lefer a m. anti-ischemic actions of a new thromboxane receptor antagonist, sq-29,548, in acute myocardial ischemia[j]. european journal of pharmacology, 1986, 122(2): 213-219. |
| | SQ 29,548 (POTENT AND SPECIFIC THROMBOXA NE A2 RECEPT Preparation Products And Raw materials |
|